Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CYTK's Cash to Debt is ranked higher than
97% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CYTK: No Debt )
CYTK' s 10-Year Cash to Debt Range
Min: 2.9   Max: No Debt
Current: No Debt

Equity to Asset 0.85
CYTK's Equity to Asset is ranked higher than
88% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CYTK: 0.85 )
CYTK' s 10-Year Equity to Asset Range
Min: -1.73   Max: 0.96
Current: 0.85

-1.73
0.96
Interest Coverage No Debt
CYTK's Interest Coverage is ranked higher than
91% of the 582 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYTK: No Debt )
CYTK' s 10-Year Interest Coverage Range
Min: 63.8   Max: 9999.99
Current: No Debt

63.8
9999.99
F-Score: 4
Z-Score: 0.69
M-Score: 4.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -33.80
CYTK's Operating margin (%) is ranked higher than
78% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. CYTK: -33.80 )
CYTK' s 10-Year Operating margin (%) Range
Min: -1961.56   Max: 32
Current: -33.8

-1961.56
32
Net-margin (%) -33.43
CYTK's Net-margin (%) is ranked higher than
77% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. CYTK: -33.43 )
CYTK' s 10-Year Net-margin (%) Range
Min: -1912.57   Max: 30.1
Current: -33.43

-1912.57
30.1
ROE (%) -24.88
CYTK's ROE (%) is ranked higher than
77% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CYTK: -24.88 )
CYTK' s 10-Year ROE (%) Range
Min: -479.2   Max: 32.47
Current: -24.88

-479.2
32.47
ROA (%) -17.93
CYTK's ROA (%) is ranked higher than
77% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. CYTK: -17.93 )
CYTK' s 10-Year ROA (%) Range
Min: -73.2   Max: 23.37
Current: -17.93

-73.2
23.37
ROC (Joel Greenblatt) (%) -1280.63
CYTK's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. CYTK: -1280.63 )
CYTK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3507.33   Max: 593.07
Current: -1280.63

-3507.33
593.07
Revenue Growth (3Y)(%) 67.10
CYTK's Revenue Growth (3Y)(%) is ranked higher than
98% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CYTK: 67.10 )
CYTK' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 154.8
Current: 67.1

0
154.8
EBITDA Growth (3Y)(%) -34.80
CYTK's EBITDA Growth (3Y)(%) is ranked higher than
59% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CYTK: -34.80 )
CYTK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -53   Max: 2.5
Current: -34.8

-53
2.5
EPS Growth (3Y)(%) -35.40
CYTK's EPS Growth (3Y)(%) is ranked higher than
61% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CYTK: -35.40 )
CYTK' s 10-Year EPS Growth (3Y)(%) Range
Min: -55   Max: 8.1
Current: -35.4

-55
8.1
» CYTK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CYTK Guru Trades in Q4 2013

Jim Simons 335,267 sh (New)
Steven Cohen Sold Out
» More
Q1 2014

CYTK Guru Trades in Q1 2014

Chuck Royce 700,000 sh (New)
Steven Cohen 700,500 sh (New)
Jim Simons 188,067 sh (-43.91%)
» More
Q2 2014

CYTK Guru Trades in Q2 2014

Paul Tudor Jones 38,969 sh (New)
Jim Simons 257,537 sh (+36.94%)
Chuck Royce Sold Out
» More
Q3 2014

CYTK Guru Trades in Q3 2014

Jim Simons 498,161 sh (+93.43%)
Paul Tudor Jones 14,228 sh (-63.49%)
» More
» Details

Insider Trades

Latest Guru Trades with CYTK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.43
CYTK's P/B is ranked higher than
88% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. CYTK: 2.43 )
CYTK' s 10-Year P/B Range
Min: 0.89   Max: 6.94
Current: 2.43

0.89
6.94
P/S 3.20
CYTK's P/S is ranked higher than
92% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. CYTK: 3.20 )
CYTK' s 10-Year P/S Range
Min: 1.39   Max: 97.81
Current: 3.2

1.39
97.81
EV-to-EBIT -6.00
CYTK's EV-to-EBIT is ranked lower than
54% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CYTK: -6.00 )
CYTK' s 10-Year EV-to-EBIT Range
Min: -13.8   Max: 7.1
Current: -6

-13.8
7.1
Current Ratio 6.28
CYTK's Current Ratio is ranked higher than
79% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CYTK: 6.28 )
CYTK' s 10-Year Current Ratio Range
Min: 1.85   Max: 23.3
Current: 6.28

1.85
23.3
Quick Ratio 6.28
CYTK's Quick Ratio is ranked higher than
80% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CYTK: 6.28 )
CYTK' s 10-Year Quick Ratio Range
Min: 1.85   Max: 23.3
Current: 6.28

1.85
23.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.76
CYTK's Price/Net Cash is ranked higher than
95% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. CYTK: 2.76 )
CYTK' s 10-Year Price/Net Cash Range
Min: 0.99   Max: 9.18
Current: 2.76

0.99
9.18
Price/Net Current Asset Value 2.72
CYTK's Price/Net Current Asset Value is ranked higher than
95% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. CYTK: 2.72 )
CYTK' s 10-Year Price/Net Current Asset Value Range
Min: 0.99   Max: 8.39
Current: 2.72

0.99
8.39
Price/Tangible Book 2.43
CYTK's Price/Tangible Book is ranked higher than
91% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. CYTK: 2.43 )
CYTK' s 10-Year Price/Tangible Book Range
Min: 0.95   Max: 5.81
Current: 2.43

0.95
5.81
Price/Median PS Value 0.19
CYTK's Price/Median PS Value is ranked higher than
98% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CYTK: 0.19 )
CYTK' s 10-Year Price/Median PS Value Range
Min: 0.11   Max: 4.95
Current: 0.19

0.11
4.95
Earnings Yield (Greenblatt) -16.70
CYTK's Earnings Yield (Greenblatt) is ranked higher than
61% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. CYTK: -16.70 )
CYTK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 14.1   Max: 238.7
Current: -16.7

14.1
238.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:KK3A.Germany,
Cytokinetics Inc was incorporated under the laws of the state of Delaware on August 5, 1997. The Company is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its research and development activities relating to the biology of muscle function have evolved from its knowledge and expertise regarding the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell. Its advanced research and development programs relates to the biology of muscle function and are directed to small molecule modulators of the contractility of skeletal or cardiac muscle. It also conducts earlier-stage research directed to other compounds with the potential to modulate muscle contractility and other muscle functions, such as growth, energetics and metabolism. Its drug candidate from its skeletal muscle contractility program, tirasemtiv, formerly known as CK-2017357, is a fast skeletal muscle troponin activator. The Company's cardiac muscle contractility program is focused on the cardiac sarcomere, the basic unit of muscle contraction in the heart. Its drug candidate from this program, omecamtiv mecarbil, formerly known as CK-1827452, is a novel cardiac muscle myosin activator that is being developed under a strategic alliance with Amgen. It is conducting joint research with Amgen directed to next-generation compounds in its cardiac muscle contractility program. The Company is currently conducting a Phase II clinical trials program for tirasemtiv, including an ongoing Phase IIb clinical trial in patients with ALS, known as BENEFIT-ALS, Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS. It is also developing CK-2127107, a structurally distinct, fast skeletal muscle troponin activator, under a strategic alliance with Astellas. The Company competes with Mitsubishi Tanabe Pharma Corporation, Eisai Inc., Trophos SA, Neuraltus Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., GlaxoSmithKline plc., BrainStorm Cell Therapeutics and Neuralstem. The Company's research, testing, manufacturing, selling and marketing of drugs are subject to extensive regulation by the FDA and other regulatory authorities in the United States.
» More Articles for CYTK

Headlines

Articles On GuruFocus.com
Cytokinetics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) Aug 04 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 25,000 Shares Jun 04 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 25,000 Shares May 20 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares May 14 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) May 07 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares Apr 28 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares Apr 01 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) Nov 05 2009 
Cytokinetics Inc. (CYTK) President & CEO Robert I Blum sells 1,000 Shares Aug 06 2009 


More From Other Websites
CYTOKINETICS INC Files SEC form 8-K, Other Events Dec 05 2014
Cytokinetics Announces Presentations Relating to Tirasemtiv & Effects on Respiratory Muscle Function... Dec 05 2014
Cytokinetics Announces Presentations Relating to Tirasemtiv and Effects on Respiratory Muscle... Dec 05 2014
Cytokinetics Announces Presentations Relating to Tirasemtiv and Effects on Respiratory Muscle... Dec 05 2014
Cytokinetics Announces Presentations Relating to Tirasemtiv at the 25th International Symposium on... Dec 01 2014
Cytokinetics Announces Presentations Relating to Tirasemtiv at the 25th International Symposium on... Dec 01 2014
Cytokinetics Announces Presentations Relating to Tirasemtiv at the 25th International Symposium on... Dec 01 2014
Can the Rally in Cytokinetics (CYTK) Shares Continue? Nov 28 2014
Cytokinetics to Participate in the 26th Annual Piper Jaffray Healthcare Conference Nov 26 2014
Cytokinetics to Participate in the 26th Annual Piper Jaffray Healthcare Conference Nov 26 2014
Cytokinetics to Participate in the 26th Annual Piper Jaffray Healthcare Conference Nov 26 2014
CYTOKINETICS INC Financials Nov 15 2014
Cytokinetics' President & CEO Robert Blum Receives 2014 Lou Gehrig Iron Horse Award From ALS Therapy... Nov 10 2014
Cytokinetics' President & CEO Robert Blum Receives 2014 Lou Gehrig Iron Horse Award From ALS Therapy... Nov 10 2014
Cytokinetics' President & CEO Robert Blum Receives 2014 Lou Gehrig Iron Horse Award From ALS Therapy... Nov 10 2014
10-Q for Cytokinetics, Inc. Nov 08 2014
CYTOKINETICS INC Files SEC form 10-Q, Quarterly Report Nov 06 2014
Can the Rally in Cytokinetics (CYTK) Shares Continue? Nov 05 2014
Cytokinetics, Incorporated (CYTK) in Focus: Stock Surges 16.2% Nov 05 2014
Cytokinetics upgraded by MLV & Co Nov 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK